2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Endothelial Dysfunction: new trials by email Literature Review of Endothelial Dysfunction trials Research Report on Endothelial Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis Aliskiren, Placebo - Endothelial Dysfunction | Phase 3 | Terminated | Mayo Clinic | 22 | 2010-02-01 | 2013-02-13 |
| Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3 valsartan (ARB), ramipril (ACE inhibitor), Placebo - Oxidative Stress, Endothelial Dysfunction | Phase 3 | Terminated | Vanderbilt University | 78 | 2010-01-01 | 2016-02-15 |
Atherosclerosis (1)
Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Cardiovascular Diseases (1) · Vascular Diseases (1)
Angiotensin-Converting Enzyme Inhibitors (1) · Ramipril (1) · Valsartan (1) · aliskiren (1)
Mayo Clinic (1) · Vanderbilt University (1)
United States (2)
Amir Lerman, MD (1) · Jonathan Himmelfarb, MD (1) · Nancy J Brown, MD (1) · Talat A Ikilzer, MD (1)
R01AG031750 (1), R01HL065193 (1), R01HL092954 (1)